Subscribe to our Newsletters !!
Infections pose an everpresent threat to society a
Biotech Fluidics has introduced a durable dual sta
A new COVID-19 variant, BA.3.2, informally called
The sustained tensions between Iran and the United
For a number of years now, healthcare systems glob
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
Biocon has gotten the Establishment Inspection Report (EIR) from the U. S. Food and Drug Administration (FDA) for the Pre-Approval and GMP examination of its Small Molecules API Manufacturing Facility at Biocon Park SEZ, Bommansandra, Bengaluru, led between 20 January and 24 January 2020. At the finish of the review the office had given a Form 483, with five perceptions, which are being tended to by the Company. The EIR has been shut with a VAI arrangement for the perceptions.
